Is rnaz a good buy

TransCode Therapeutics, Inc. (RNAZ) is not a good buy at this time. Here are the key reasons:

1. Financial Performance: RNAZ reported a net loss of $5.19 million and a diluted EPS of -$0.74 for the latest quarter. The company's total revenue was$-0.01 million, with a revenue growth rate of -122.90% and a net income growth rate of -2.06%. These figures indicate that the company is currently unprofitable and facing significant revenue and net income declines.

2. Stock Price Movement: The stock's price has experienced a significant drop, which could be indicative of investor skepticism about the company's future prospects. The current stock price is near the support level of $0.51, which could indicate weak demand.

3. Clinical Trial Progress: The company has initiated a Phase 1 clinical trial for its leading drug candidate, TTX-MC138, which is a positive development. However, the outcome of clinical trials is uncertain, and the company may not meet its development milestones.
4. Market Sentiment: The company has a negative short interest ratio, indicating that a large percentage of outstanding shares are short, which could suggest that investors are bearish on the stock.

In conclusion, the current financial losses, stock price decline, and negative market sentiment indicate that RNAZ is not a good buy at this time. Investors should exercise caution and consider the high risk associated with the company's current situation.